On October 12, 2026, a new publication on bivalirudin appeared in the Journal of Pharmaceutical and Biomedical Analysis. The paper is titled "Comprehensive analysis of peptide pharmaceutical: Development of three orthogonal chromatographic methods and characterization of bivalirudin degradation products by high-resolution mass spectrometry."
The publication describes the development of three orthogonal chromatographic methods. It also addresses the characterization of bivalirudin degradation products using high-resolution mass spectrometry. Bivalirudin remains an approved peptide pharmaceutical.
This brief reports only the existence and stated focus of the publication as described in its title and journal listing. No specific findings, results, or conclusions from the study are detailed here. Readers interested in the full analytical methods and characterization data should consult the original publication directly through the provided source link.
For additional background on bivalirudin, including its regulatory status and general profile, readers can refer to the compound overview.